Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rallybio (RLYB) EBITDA (2023 - 2025)

Historic EBITDA for Rallybio (RLYB) over the last 3 years, with Q3 2025 value amounting to $16.0 million.

  • Rallybio's EBITDA rose 24273.12% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.3 million, marking a year-over-year increase of 7850.47%. This contributed to the annual value of -$57.7 million for FY2024, which is 2234.88% up from last year.
  • Per Rallybio's latest filing, its EBITDA stood at $16.0 million for Q3 2025, which was up 24273.12% from -$9.7 million recorded in Q2 2025.
  • In the past 5 years, Rallybio's EBITDA ranged from a high of $16.0 million in Q3 2025 and a low of -$20.0 million during Q4 2023
  • Its 3-year average for EBITDA is -$12.3 million, with a median of -$16.2 million in 2024.
  • As far as peak fluctuations go, Rallybio's EBITDA plummeted by 1136.03% in 2024, and later soared by 24273.12% in 2025.
  • Over the past 3 years, Rallybio's EBITDA (Quarter) stood at -$20.0 million in 2023, then soared by 44.33% to -$11.1 million in 2024, then soared by 243.77% to $16.0 million in 2025.
  • Its EBITDA stands at $16.0 million for Q3 2025, versus -$9.7 million for Q2 2025 and -$9.5 million for Q1 2025.